Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

PDL Biopharma Inc (PDLI) Com Stk USD0.01

Sell:$3.15 Buy:$3.16 Change: $0.18 (5.41%)
Market closed |  Prices as at close on 30 September 2020 | Switch to live prices |
Change: $0.18 (5.41%)
Market closed |  Prices as at close on 30 September 2020 | Switch to live prices |
Change: $0.18 (5.41%)
Market closed |  Prices as at close on 30 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PDL BioPharma, Inc. is focused on developing therapeutics and healthcare technologies. Through its subsidiary, LENSAR, Inc., the Company provides medical devices. It is focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It has developed the LENSAR Laser System, which is the femtosecond cataract laser built for refractive cataract surgery. LENSAR Laser System offers cataract surgeons automation and customization for their astigmatism treatment planning and other steps of the refractive cataract surgery procedure. It assists surgeons in managing their astigmatism treatment plans for optimal overall visual outcomes.

Contact details

932 Southwood Blvd
United States
+1 (775) 8328500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$379.56 million
Shares in issue:
113.98 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Elizabeth O'Farrell
    Chairperson of the Board
  • Dominique Monnet
    President, Chief Executive Officer, Director
  • Edward Imbrogno
    Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
  • Christopher Stone
    Vice President, General Counsel, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.